C hronic rhinosinusitis (CRS) is a condition characterized by inflammation of the paranasal sinuses and lining of the nasal cavity for 12 weeks or more. 1 It is primarily an inflammatory disease, with occasional exacerbations associated with infection. Though relatively common, the disease burden associated with CRS is substantial. Patients with CRS visit primary care clinicians twice as often as those without CRS and have 5 times as many prescriptions filled. 2 A survey performed in 2007 found that approximately $8.3 billion is spent annually on CRS, primarily on prescription drugs and office-based care. 3 The recommended medical management of CRS includes large-volume, low-pressure saline nasal lavage, systemic antibiotics, and topical nasal steroid sprays. 4, 5 While systemic antibiotics are useful to treat episodic exacerbations of CRS, there is little evidence to recommend them as long-term treatment. Nevertheless, antibiotics are often prescribed for CRS, and national surveys suggest a large degree of overutilization, which is associated with the development of serious adverse effects and resistant organisms. [6] [7] [8] In contrast, topical nasal steroid sprays have been shown to be safe and effective in the long-term management of CRS. [9] [10] [11] There is evidence, however, that the penetration of steroid beyond the nasal cavity and into the paranasal sinuses is limited, indicating that a novel delivery method is needed to improve intrasinus corticosteroid deposition. [12] [13] [14] A recent systematic review by Thomas et al 15 analyzed various ways to distribute topical therapeutics to the sinuses in patients with CRS. The authors found that large-volume, lowpressure irrigation devices resulted in better distribution to the nasal cavity and sinuses, especially after surgery, than lowvolume devices. Large-volume, low-pressure saline sinus irrigation is a widely recommended treatment for CRS, which is low cost and has a high patient acceptance and benefit-torisk margin. [16] [17] [18] [19] [20] Three recent prospective cohort studies examined the use of large-volume, low-pressure, saline sinus irrigation to deliver budesonide, an anti-inflammatory glucocorticoid steroid used for the treatment of allergic rhinitis, nasal polyps, and chronic obstructive pulmonary disease. [21] [22] [23] All 3 studies demonstrated statistically and clinically significant subjective improvement in sinus disease after treatment. In addition, 2 of the studies documented significant improvement in objective measures of sinus disease. 21, 23 The objective of the present study was to evaluate the effect of the addition of budesonide to large-volume, low-pressure saline sinus irrigation for patients with CRS in a double-blind, placebo-controlled, randomized clinical trial using both subjective and objective outcome measures.
Methods

Study Design and Participants
This study was a single-site, double-blinded, placebo-controlled, randomized clinical trial of patients with CRS. The trial protocol can be found in the Supplement, and the trial is registered at ClinicalTrials.gov (NCT02696850). The flow diagram of study enrollment and participation is shown in Figure 1 . Men and women 18 years or older with a diagnosis of CRS were recruited from the Otolaryngology Clinic of the Washington University in St Louis School of Medicine from January 1, 2016, to February 16, 2017 . The study was approved by Washington University's Human Protection Research Office. All participants provided written informed consent.
Study participants were required to have inflammation of the sinuses, as documented by the recruiting physicians (J.S. and J.F.P.), for 12 weeks or longer and 2 or more of the following symptoms consistent with CRS: mucopurulent drainage (anterior, posterior, or both), nasal obstruction, facial painpressure-fullness, and decreased sense of smell.
Patients with a history of comorbid mucociliary conditions; antibiotic use in the 2 weeks prior to enrollment; sinus surgery in the 6 weeks prior to enrollment; cerebrospinal fluid leak; allergy to topical steroids; tuberculosis lung infection; and/or herpes eye infection were excluded. In addition, patients were excluded if they were pregnant, breastfeeding, or dependent on prolonged corticosteroid therapy for a comorbid condition.
Severity of overall comorbidity was assessed with the Adult Comorbidity Evaluation-27 (ACE-27) instrument. 24 The ACE-27 is a valid comorbidity instrument that rates the degree of organ decompensation for a variety of different comorbid ailments and then generates an overall score (none, mild, moderate, or severe) based on the rating for individual ailments.
Interventions
All study participants were provided with an 8-ounce Sinus Rinse Regular Bottle Kit (NeilMed Pharmaceuticals Inc) and a 1-month supply of United States Pharmacopeia (USP) grade sodium chloride and sodium bicarbonate mixture. Participants were asked to either purchase distilled water or to boil tap water for 5 minutes to use with the saline irrigation. A randomized block design was generated by the study statistician (D.K.), and the study coordinator (S.K.) consecutively assigned participants to the treatment or control groups after enrollment. Participants randomized to the treatment group received 60 capsules of budesonide (0.5 mg/capsule), while participants randomized to the control group received 60 identical-appearing capsules of lactose. Each study bottle was assigned a number from 1 to 80 corresponding to the randomization schedule. The participants and all members of the study team except the study statistician were blinded to the randomization assignment. Participants were instructed to dissolve 2 capsules of the study drug into the sinus rinse bottle along with the saline, and to irrigate the left and right nasal cavity with one-half of the contents of the nasal rinse once daily for 30 days. All participants received verbal and written instructions on how to conduct the irrigation properly.
Patient-Reported Outcome Measures
The primary outcome measure was the intraparticipant change, pretreatment to posttreatment, in Sino-Nasal Outcome Test (SNOT-22) scores in the budesonide group compared with the control group. The SNOT-22 is a validated, patient-reported outcome measure that captures the physical, functional, and emotional consequences of rhinosinusitis. 25 The SNOT-22 score is calculated as the sum of scores provided for each question and ranges from 0 to 110. All participants were asked to complete the SNOT-22 at baseline, 2 weeks, and after intervention (approximately 4 weeks after baseline). A minimal clinically important difference (MCID) in SNOT-22 scores was considered an improvement of at least 8.9 points, as described previously. 25, 26 Patients with a baseline SNOT-22 score below 9 were excluded because these patients would be unable to achieve MCID. The secondary outcome measure was the patientreported response to treatment, as measured with a modification of the Clinical Global Impressions (CGI) scale. 27 The CGI questionnaire was given to all participants after intervention, and they were asked to rate their overall response to treatment using a 7-point Likert scale.
Objective Outcome Measure
Objective change in sinus disease was assessed with endoscopic examination by the recruiting otolaryngologist (J.S. and J.F.P.) at baseline and postintervention. Findings were recorded using the Lund-Kennedy grading system. 28 
Statistical Analysis
The sample size was estimated using preliminary data reported by Snidvongs et al. 21 Using a 2-sided α of .05, with 80% power, it was estimated that a sample size of 32 participant per group (total n = 64) would be needed to detect an MCID of 9 points or greater in SNOT-22 scores from before to after treatment between the 2 treatment groups. Anticipating a 20% dropout rate, we set the sample size at 80 qualifying enrollees. Descriptive statistics were used to summarize the demographic and clinical characteristics and assessments of the study population. The effect size was measured as the pretreatment to posttreatment change in SNOT-22 scores. The 95% confidence interval (CI) around the difference was calculated and used to assess for clinically meaningful differences between the 2 treatment groups. Recognizing the variability in individual responses and the distortion this variability can cause in summarizing treatment effects as a difference in means, the observed difference in the percentage of participants who achieved an MCID between the 2 treatment groups and the 95% CI around this percentage difference was calculated. 29 A mixed general linear model approach was used to explore whether the magnitude and pattern of change in SNOT-22 scores between baseline and postintervention was different in the 2 treatment groups, and to estimate mean scores in the 2 groups after controlling for confounders.
All analyses were repeated within subgroups of nasal polyp and previous surgery participants. An interim analy- sis was performed after participant 32 was enrolled in the study to assess compliance with treatment and response to treatment. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute Inc). Statistical significance was evaluated at the 2-sided α level of .05. Effect size and 95% CIs around the effect size are reported.
Results
A total of 80 patients were enrolled in the study between January 1, 2016, and February 16, 2017, and were randomized to either budesonide (n = 40) or placebo (n = 40) saline nasal lavage. Six participants withdrew after randomization, and 74 completed baseline assessments and started their assigned interventions. Thirteen participants were lost to follow-up, and 61 completed the intervention and postintervention assessments ( Figure 1 ). The baseline characteristics of all participants are summarized in the Table. The mean (SD) age was 51 (14.7) years, and most participants were women (n = 50; 68%) and of white race (n = 67; 90%). Approximately half of the participants had no other comorbidities (n = 41; 53%), and 7 (9%) reported moderate or severe comorbidities.
There were 18 (25%) participants identified as having nasal polyps during medical examination and 21(28%) participants who reported having prior sinus surgery. The mean (SD) endoscopic score at initial visit was 5.3 (2.2) points, and the mean (SD) SNOT-22 score was 44.1 (18.5) . No significant differences were found between treatment groups in the distribution of baseline demographic characteristics, comorbidity, endoscopic scores, SNOT-22 scores, or history of sinus surgery. The percentage of participants with polyps was higher in the budesonide group (n = 12; 34%) than in the saline nasal lavage group (n = 6; 16%), for a difference of 18% (95% CI, −2 to 37).
There were 29 participants randomized to budesonide treatment and 32 to saline nasal lavage who completed postintervention study assessments. The mean (SD) change in SNOT-22 scores for participants in the budesonide group was 20.7 (17.9) points, and for those in the saline nasal lavage group, it was 13.6 (18.8) points, for a mean difference of 7 points in favor of the budesonide group (95% CI, −2 to 16) and a Cohen d of 0.39 (medium effect size) ( Figure 2) . A mixed withinbetween participants model was used to explore the change in SNOT-22 score from before to after intervention and to test whether this change was significantly different between the 2 study groups. The interaction effect between time of assessment and treatment group was not statistically significant. There was 1 patient who completed the study assessment but was not compliant with treatment in the budesonide group. When the noncompliant participant was excluded, a mean (SD) decrease in SNOT-22 scores of 22.1 (16.3) was observed in the budesonide group, corresponding to a mean difference in the change in SNOT-22 scores between treatment groups of 8.5 (95% CI, −0.6 to 18.0). The mean (SD) change in endoscopic scores from before to after intervention was 3.4 (2.3) points for participants in budesonide group and 2.7 (1.9) points for those in the placebo group. The average difference of the change between participants in the 2 groups was 0.7 points (95% CI, −0.6 to 2.0 points) in favor of the budesonide group. A reduction of 9 or more points in SNOT-22 score was considered clinically meaningful. A total of 23 participants (79%) in the budesonide group experienced a reduction of 9 or more points in their SNOT-22 scores compared with 19 (59%) of those in the saline nasal lavage group, for an observed difference of 20% (95% CI, −2.5% to 42.5%) ( Figure 3 ) and an odds ratio of 2.6 (95% CI, 0.84-8.2). When the noncompliant budesonide participant was excluded, 82% in the budesonide group achieved the MCID, for an observed difference of 23% (95% CI, 1%-45%) and an odds ratio of 3.15 (95% CI, 0.95-10.42) in favor of budesonide.
We investigated the role of polyps, history of sinus surgery, and comorbidity as potential confounders of the effect of budesonide treatment. Based on SNOT-22 scores, none of the variables were found to be confounders.
We explored the effect of budesonide treatment among the participants with nasal polyps. Among participants with no polyps, there was an average difference of 10.2 points (95% CI, −1.6 to 22.1) in the change in SNOT-22 scores between the budesonide (n = 18) and saline nasal lavage treatment (n = 26) groups. Among participants with polyps, there was an average difference of −4.1 points (95% CI, −20.4 to 12.2) in the change in SNOT-22 scores in the budesonide group (n = 10) compared with the saline nasal lavage group (n = 6) ( Figure 4A ).
In participants with a history of sinus surgery, a mean difference of −0.1 points (95% CI, −19.6 to 19.4) was observed in the change in SNOT-22 scores between the budesonide (n = 9) and saline nasal lavage groups (n = 9). In participants with no prior sinus surgery, a mean difference of 10.1 points (95% CI, −1.1 to 21.3) was observed in SNOT-22 scores between the budesonide (n = 20) and saline nasal lavage groups (n = 23) ( Figure 4B ).
Based on CGI, 24 participants (83%) in the budesonide group and 20 (67%) in the saline nasal lavage group selfreported that they were "minimally improved," "much improved," or "very much improved." The observed difference in the percentage of participants who self-reported some degree of improvement between the 2 arms was 16% (95% CI, −6% to 38%) in favor of the budesonide group. There were no related adverse events in either intervention group.
Discussion
In this double-blind, placebo-controlled, randomized clinical trial, we found that the addition of 1 mg of budesonide to daily large-volume, low-pressure saline sinus irrigation for 1 month resulted in a clinically meaningful improvement in self-reported functional status and quality of life measures as well as objective measurements of CRS. The estimates of benefit were imprecise, and while the confidence interval does not exclude the possibility of no effect in the population, the upper bound of the confidence interval suggests that this effect can also be very strong. A greater benefit of budesonide was seen among patients with no history of surgery than in those who had undergone surgery, contrary to current understanding that surgical opening of the sinuses is required for medicated saline lavage to be effective. The presence of polyps was greater in the budesonide arm and was associated with a smaller improvement in symptoms with budesonide than when polyps were not present. Budesonide was well tolerated, and there were no reported adverse events associated with its use.
Currently, CRS is primarily treated as an infectious disease process with frequent administration of antibiotics. Research suggests that as much as 50% of the antibiotics prescribed for sinusitis may be inappropriate and associated with harm. 7 As a result, multiple national organizations, including the Centers for Disease Control and Prevention (CDC), have begun antibiotic stewardship programs to measure and improve how antibiotics are prescribed by clinicians and used by patients. Among specialists, there is a growing recognition that CRS may reflect a dysfunctional immune interplay between different host susceptibilities and environmental modifiers that are responsible for the chronic inflammatory response. 30, 31 This dysfunctional interplay creates targets for nonantibiotic therapy in chronic sinusitis. As there are a variety of different "phenotypes" of CRS, including patients with and without polyps, it is likely that there are a variety of different abnormalities within the innate and adaptive immune system or "endotypes" that can serve as targets for therapy. 31 This new area of potential treatment is referred to as "biologic therapy," and potential targets for therapy include epithelial cell-derived cytokines and IgE. Saline nasal lavage has been shown to be an effective form of treatment for sinusitis and can be an effective delivery system for various therapeutics, including corticosteroids. Large-volume, low-pressure nasal lavage results in better distribution of therapeutics to the nasal cavity and sinuses than low-volume devices. 15 Furthermore, these large-volume, lowpressure devices can mediate adverse effects of head position or nasal cavity anatomy on distribution. 14, 18 Saline nasal lavage is low cost and has both high patient acceptance and a high benefit-to-risk margin. 17, 19 Though the evidence regarding large-volume saline irrigation is promising, more highquality evidence is needed to definitively establish its benefit compared with other forms of treatment such as nasal spray. 16, 27 The impact of budesonide added to saline nasal lavage for the treatment of CRS has been investigated with several prospective cohort studies. Sachanandani et al 22 formed a similar study evaluating budesonide saline nasal irrigation treatment in 8 patients with CRS and demonstrated similar significant improvements in several objective and subjective sinus outcome measures. The conclusions from these studies, while promising, were largely speculative given the small sample sizes. Most recently, Snidvongs et al 21 demonstrated significant and sustained objective and subjective clinical improvement in a large cohort of patients with CRS treated after endoscopic sinus surgery with topical steroid nasal irrigations. All 3 of these studies have been limited, however, by lack of a control group.
In the present trial, we observed a clinically significant benefit of budesonide among patients who had not had previous sinus surgery. These results are surprising and suggest that a large number of patients with CRS would benefit from budesonide without sinus surgery. The mechanism for this benefit is unclear as, previous research 15 has suggested that the distribution of topical agents is significantly reduced without prior sinus surgery. The benefit found in the present study of budesonide among participants without a history of sinus surgery may be explained by many factors, including the ability of the budesonide molecule to stick to nasal mucosa and, through reduction of inflammation, allow penetration of the sinus cavities. We also observed that patients with nasal polyps had only a minor benefit of budesonide. Patients with nasal polyps may have reduced topical application and penetration of budesonide and thus less beneficial effects. Furthermore, patients with nasal polyps may have endotypes that are less responsive to the anti-inflammatory effects of the glucocorticosteroids.
Limitations
There are several limitations to this study. First, the duration of the trial was only 4 weeks and, given the long duration of symptoms and chronic nature of the condition for many participants, this may have been an insufficient amount of 
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The horizontal lines within the boxes represent mean change in Sino-Nasal Outcome Test (SNOT-22) score; the bottom and top lines of the boxes, 25th and 75th percentiles; the whiskers extending below and above the boxes, the minimum to the 25th percentile and 75th percentile to the maximum, respectively; and the circles above and below some of the graphs, outlier cases. A SNOT-22 score change of 9 points is deemed clinically meaningful.
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Research Original Investigation Effect of Budesonide Added to Saline Sinus Irrigation for Chronic Rhinosinusitis time to see the complete effect of the budesonide therapy. Compliance was assessed by patient self-report, as we did not have formal compliance assessments. Thus, we cannot be certain that participants completed the full 4 weeks of treatment. Despite these limitations, the observed magnitude of the benefit of budesonide was clinically significant, as evidenced by the effect size, and the true effect could be even greater, as evidenced by the upper bound of the 95% CIs. However, the low precision of the estimates of the effect, as demonstrated by the width of the 95% CIs, and the inclusion of the null for many of the comparisons, undermines our ability to make definitive conclusions from this trial. Furthermore, the size of certain subgroups, such as those with nasal polyps, was so small and unequally divided between the 2 treatment groups as to further prohibit definitive conclusions.
Conclusions
This study shows that the use of budesonide in large-volume, low-pressure saline nasal lavage results in clinically meaningful benefits for patients with CRS. Additional randomized clinical trials of the effect of budesonide in saline nasal lavage for those with CRS vs saline-alone controls and, furthermore, budesonide vs steroid nasal spray are needed and will help define the true effect of budesonide within unique patient subgroups. Owing to our limited understanding of the pathophysiology of chronic rhinosinusitis (CRS), expansion of the armamentarium of medical therapies for CRS has remained notably constrained for decades. Over the last 30 years, advances in medical treatment for CRS have not kept pace with innovations in surgical treatment. And yet, since many physicians believe that CRS remains a medical disease first and foremost, there is often a sense of frustration that we do not have more innovative medical therapies to offer our patients with CRS.
Clinicians have often resorted to off-label use of medications in the treatment of CRS, a reflection of a need and desire to offer a broader range of therapeutic options to our patients. Without rigorous regulatory standards to guide their use, off-label prescribing of medications is often associated with spottily documented efficacy and safety. For example, despite widespread use of oral antibiotics by practitioners in the treatment of CRS, 1 there are still no antibiotics that are approved by the US Food & Drug Administration for CRS, and the evidence to support routine antibiotic use in CRS remains low. 2 Topical antibiotics are another category of medication favored by many otolaryngologists treating patients with CRS, yet the evidence for their efficacy is surprisingly slim.
2
Topical corticosteroid irrigation is another commonly used off-label medical therapy for CRS. Although highly favored among clinical experts and increasingly prevalent in general otolaryngologic practice, topical corticosteroid irrigation therapies have a relatively small body of literature to support their use in terms of efficacy and safety. As a result, many insurance carriers have chosen not to cover corticosteroid irrigations, leaving patients to self-pay for a therapy that many patients and their physicians find beneficial. Without the backing of pharmaceutical industry funding for large-scale clinical trials, the burden of proof for establishing the safety and efficacy of topical corticosteroid irrigations has fallen on independent investigators.
Tait et al 3 have executed a well-designed randomized clinical trial comparing budesonide irrigation with plain saline irrigation. The study evaluated 80 patients with CRS randomized to once-daily nasal irrigation with either 1.0 mg of budesonide plus saline or placebo plus saline, administered via a high-volume rinse bottle, for 30 days. The authors found that patients receiving budesonide had an average of 7 points greater reduction in the SNOT-22 score (Sino-Nasal Outcome Test) compared with those receiving placebo (medium effect size). However, the 95% confidence interval for the difference between groups in pretreatment vs posttreatment scores did include 0, leading the authors to acknowledge that "the estimates of benefit were imprecise, and…the confidence interval does not exclude the possibility of no effect." 3 Furthermore, there were interesting and perhaps unexpected findings in the subgroup analysis, suggesting that subgroups of patients with CRS may have differential responses to budesonide irrigations. For example, those patients with CRS without nasal polyps showed a greater reduction in SNOT-22 scores with budesonide irrigation than those with nasal polyps. In addition, patients with a history of prior sinus surgery showed minimal symptomatic benefit from budesonide irrigation vs placebo, whereas patients without prior surgery showed a greater benefit from budesonide irrigation vs placebo. Subgroup analysis was limited by smaller numbers in each of the comparison cohorts, and the 30-day duration of treatment was relatively short.
While this well-structured randomized clinical trial offers level 1 evidence for assessing the value of budesonide irrigations in patients with CRS, there are many questions raised by this report that require further study to understand its clinical applicability. Given our understanding of CRS as a heterogeneous disease process, a much larger study appears necessary to enable statistically sound subgroup analysis; this is necessary to achieve clarity on which subgroups of those with CRS may experience the greatest benefit from budesonide irrigations. In addition, while the choice of a saline placebo group is reasonable from the standpoint of study design, practically 
Abstract
Chronic rhinosinusitis (CRS) is a condition characterized by inflammation of the paranasal sinuses and lining of the nasal cavity for 12 weeks or more. The characteristic symptoms of rhinosinusitis include facial pain-pressure-fullness, and nasal discharge accompanied by nasal obstruction. Rhinosinusitis is exceedingly common and estimates suggest that 1 in 8 adults are affected and over 30 million cases are diagnosed each year. Analysis of national ambulatory data demonstrates that rhinosinusitis accounts for more outpatient antibiotic prescriptions than any other diagnosis.
CRS is primarily an inflammatory disease, with occasional exacerbations associated with infection. Treating the episodic infections alone leaves the underlying condition untreated, likely contributing to an increased frequency of exacerbations. CRS is associated with sinus edema and impaired mucociliary clearance. With edema-related obstruction and retained mucus, bacterial infection can more easily occur.
Nasal sinus saline irrigation (aka Neti-Pot) is widely recommended and is a common treatment for CRS. The use of either isotonic ("normal" saline) or hypertonic saline is recommended and exact recommendations for amount of volume vary substantially. There have been over 12 studies (10 RCTs, 1 systematic review, and 1 meta-analysis) examining the impact of saline irrigation in the management of CRS. Both of the reviews concluded that nasal saline irrigation is an effective treatment for CRS with a high benefit to risk margin. Nasal saline irrigation is low-cost, has an excellent safety profile, and has high patient acceptance, which make it an appealing long-term topical treatment strategy.
Budesonide is an anti-inflammatory glucocorticoid steroid that is used for a variety of common ailments. Among conditions related to the respiratory tract, budesonide is used as an inhalational drug for the treatment of asthma, COPD, allergic rhinitis, and nasal polyps. Three studies examined the use of topical budesonide delivered through low-pressure, high-volume saline irrigation. All three studies reported dramatic improvement in symptoms with minimal local or systematic effects.
The goal of this research project is to explore the impact of the addition of budesonide to high-volume, low-N -P -type systems) for patients with chronic rhinosinusitis with or without nasal polyps.
The specific aims of this study are as follows: 1. To determine the incremental benefit of the addition of budesonide to nasal irrigation for CRS patients. 2. To describe the adverse effects related to budesonide nasal saline irrigation.
To answer the research question, the study design will be a double-blind placebo-controlled randomized clinical trial. Up to 80 adult patients with complaints of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both and reduction or loss of smell for 12 weeks or greater will be eligible. The intervention will be 4 weeks of budesonide powder added to saline rinse or lactose placebo added to saline rinse alone. The primary outcome measure will be the average perpatient change in the SNOT-22 between the two treatment groups.
SYNOPSIS
Study Title
The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis Objective
The objective of this research project is to explore the impact of the addition of budesonide to low-pressure, high-volume saline nasal irrigation ( N -P patients with chronic rhinosinusitis with or without nasal polyps.
Study Period
Planned enrollment duration for each subject: 1 month Planned study duration: I year
Number of Patients
Up to 80 adult patients with complaints of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both and reduction or loss of smell for 12 weeks or greater.
Study Drug
Budesonide and identical appearing placebo containing lactose. Budesonide is an anti-inflammatory glucocorticoid steroid that is used for a variety of common ailments.
Study Design
Prospective, double-blind, placebo-controlled randomized clinical trial
Inclusion and Exclusion Criteria
Inclusion Criteria: Twelve (12) Tuberculosis (TB) lung infection, or Herpes infection of the eye.  Baseline SNOT-22 total scores below 9 were excluded due to the inability to achieve a minimally clinically improved difference  Known history of bleeding disorder, topical or injectable lidocaine allergy, use of blood thinners
Primary Outcome
The change in the SNOT- Within subject change in SNOT-22 between intervention groups. Sub-group analyses will be performed for patients with and without polyps and prior history of sinus surgery
Statement of the Research Problem Definition and Burden of Rhinosinusitis
Chronic rhinosinusitis (CRS) is a condition characterized by inflammation of the paranasal sinuses and lining of the nasal cavity for 12 weeks or more. 3 The characteristic symptoms of rhinosinusitis include facial pain-pressure-fullness, and nasal discharge accompanied by nasal obstruction. Rhinosinusitis is exceedingly common and estimates suggest that 1 in 8 adults are affected and over 30 million cases are diagnosed each year. 4, 5 Analysis of national ambulatory data demonstrates that rhinosinusitis accounts for more outpatient antibiotic prescriptions than any other diagnosis. 6 Patients with CRS visit primary care clinicians twice as often as those without the disorder and have 5 times as many prescriptions filled. 7 . A survey performed in 2007 found that approximately $8.3 billion is spent annually on CRS, primarily on prescription drugs and office-based care. 8 Surgery, which costs on average $7,700 per patient, is performed nearly 250,000 times per year in the United States 9 In September 2005, the balloon sinuplasty device received FDA approval as the first catheter-based system for dilation of the paranasal sinuses. This minimally invasive procedure has caught the attention of the media and the public and its rate of adoption within the otolaryngology community has been rapid, albeit with controversy surrounding its indications and outcomes.
CRS is primarily an inflammatory disease, with occasional exacerbations associated with infection. Treating the episodic infections alone leaves the underlying condition untreated, likely contributing to an increased frequency of exacerbations. In this way, CRS is very similar to chronic bronchitis. CRS is associated with sinus edema and impaired mucociliary clearance. With edema-related obstruction and retained mucus, bacterial infection can more easily occur. 10 Mucus hypersecretion is a hallmark of chronic rhinosinusitis (CRS) and is associated with several common symptoms. Mucin 5AC (MUC5AC) is a major respiratory mucin gene that codes for a gelforming mucin glycoprotein found in the gastric and respiratory epithelia. MUC5AC is overexpressed in CRS patients both with and without nasal polyps . [1] [2] [3] [4] [5] [6] Furthermore, CRS is associated with changes in nasal epithelial tissue, including epithelial damage and an increase in basement membrane thickness . [7] [8] [9] 
Medical Management
The medical management of CRS includes antibiotics, topical nasal steroid sprays, saline irrigation. Antibiotics are often prescribed for CRS and national surveys suggest a large degree of over utilization with development of serious adverse side effects and resistant organisms.
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Nasal Sinus Irrigation
Nasal sinus saline irrigation (aka Neti-Pot) is widely recommended and is a common treatment for CRS. The use of either isotonic ("normal" saline) or hypertonic saline is recommended and exact recommendations for amount of volume vary substantially. There have been over 12 studies (10 RCTs, 1 systematic review, and 1 meta-analysis) examining the impact of saline irrigation in the management of CRS. Of these 12 studies one was a systematic review and the other was a meta-analysis 18, 25 Both studies concluded that nasal saline irrigation is an effective treatment for CRS with a high benefit to risk margin. Nasal saline irrigation is low-cost, excellent safety profile, and high patient acceptance make it an appealing long-term topical treatment strategy.
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Topical Nasal Steroid Spray
The impact of intranasal corticosteroid sprays (INCS) in patients with CRS without polyps was explored with two high quality systematic reviews. In the first published in 2009, Kalish et al. 27 reviewed 424 potential studies and only nine randomized trials involving 657 patients were eligible. Of these nine studies, only 5 were acceptable for further inclusion. The summary estimate for overall response to treatment showed no significant benefit and substantial variability among studies (5 trials: RR 0.75, 95% CI 0.50-1.10, P = 0.14, chi(2) = 13.78, I(2) = 66.2%). Total symptom score was reported in three trials with a standardized mean difference favoring topical steroids. The authors concluded that there is insufficient evidence to demonstrate a clear overall benefit for topical steroids in CRS without polyps; however, their use appears safe and may show some symptomatic benefit. Snidvongs et al. 28 published a Cochrane Review in 2011 that combined 5 trials reporting symptom scores. When compared to placebo, topical steroid improved symptom scores (standardised mean difference -0.37; 95% confidence interval (CI) -0.60 to -0.13, P = 0.002; five trials, n = 286) and had a greater proportion of responders (risk ratio 1.69; 95% CI 1.21 to 2.37, P = 0.002; four trials, n = 263). The authors' concluded that topical steroid is a beneficial treatment for CRS without polyps and the adverse effects are minor. The authors also concluded that direct topical delivery of steroid to the sinuses may bring more beneficial effect than simple nasal delivery and that further studies comparing different topical drug delivery methods to the sinuses are warranted.
While the use of INCS is generally recommended in the setting of CRS, there is evidence of the limited penetration of the steroid beyond the nasal cavity and into the paranasal sinuses 29, 30 . Therefore, there has been great interest in the use of novel delivery approaches and devices to improve intra-sinus corticosteroid deposition. 
Non-Standard Delivery of Topical Steroids
Three studies examined the use of topical steroids delivered through low-pressure, high-volume saline irrigation. Snidvongs et al. 32 published a prospective cohort of 111 patients, 49 of whom had a diagnosis of CRS without nasal polyps. Treatment was with once daily nasal irrigations of 1mg budesonide/betamethasone in 240 ml of normal saline in the immediate post-operative period. Significant improvements were seen in SNOT-20 scores (2.3 +/-1.1 vs 1.2 +/-0.9), symptom scores (2.5 +/-1.1 vs 1.4 +/-1.0) and Lund-Kennedy endoscopy scores (4.3 +/-2.0 vs 1.9 +/-1.6). No adverse outcome analysis was reported. Another study, completed by the PI and colleagues at Washington University 33 , was an open-label prospective study enrolling 9 subjects. Subjects received a 30 day course of 250 µg budesonide diluted into 5 mL of isotonic saline and delivered into each nostril QID. Subjects also underwent adrenal function assessment with the cosyntropin test before and after budesonide therapy. All subjects showed adequate adrenal response to cosyntropin stimulation before and after the budesonide trial and the mean change in SNOT-20 scores before and after budesonide therapy was statistically and clinically improved. Steinke 34 conducted a prospective pilot study in 8 subjects with allergy as defined by a positive skin prick test and 4 subjects were classified as having aspirinexacerbated respiratory disease, and all but 1 had physician-diagnosed asthma. The subjects received a 3-. The median sinus CT score before treatment was 15 (maximum, 30), which improved to 5 (P < .05) after treatment. Based on a visual analog scale, the authors we calculated scores for each of 16 sinus symptoms on a scale of 0 to 6, with 6 being severe and A decreased (mean ± SD) from 43.1 ± 5.4 to 20.1 ±3.0 (P<.02). In addition, subjects reported a significant improvement in sense of smell. Of the four patients with nasal polyps, three had complete resolution.
The authors concluded that their study supports the concept that addition of budesonide inhalation suspension to standard nasal saline irrigation produces subjective and objective benefit in eosinophilic sinus disease and that a double-blind, placebo-controlled study of budesonide inhalation suspension in nasal saline washes for patients with CRS was warranted.
Specific Aims
The goal of this research project is to explore the impact of the addition of budesonide to low-pressure, high-volume nasal sinus saline irrigation (aka N -P with or without nasal polyps.
The Specific Aims of this study are as follows:
To determine the incremental benefit of the addition of budesonide to nasal irrigation for CRS patients.
Hypothesis: Budesonide is a topical corticosteroid with potent anti-inflammatory properties and when delivered via nasal saline irrigation will be more effective than normal saline alone in the treatment of symptoms associated with chronic rhinosinusitis. To evaluate this hypothesis a double-blind randomized clinical trial will be performed among adult subjects presenting to Washington University Department of Otolaryngology-Head and Neck Surgery for the treatment of chronic rhinosinusitis. The primary outcome measure will be the within subject change in SNOT-22 scores among subjects in the two arms of the study after four weeks of daily low-pressure, high volume sinus irrigation containing either isotonic saline and budesonide or isotonic saline alone.
To describe the adverse effects related to budesonide nasal saline irrigation.
Subjects will be queried regarding adverse events experienced during participation in the study and a determination of the likely association with budesonide will be made.
Experimental Plan, Methods, and Data Analysis Study Design
Double-blind placebo-controlled randomized clinical trial
Subjects
Inclusion Criteria:
Twelve (12) or Herpes infection of the eye.  Baseline SNOT-22 total scores below 9 were excluded due to the inability to achieve a minimally clinically improved difference
Variables of Interest
Demographic -age, gender, and race.
Index condition Duration of CRS symptoms, response to previous treatments
Co-morbid conditions -Presence and severity of general comorbid conditions will be assessed with ACE-27. 35 Presence of rhinosinusitis-specific comorbidities will include: inhalant allergies, asthma, and aspirin sensitivity Previous sinus and/or nasal surgery -Previous sinus and/or nasal surgery, including functional endoscopic sinus surgery, turbinate reduction, and septoplasty will be captured and duration since surgery to time of enrollment.
Randomization
The study statistician, Dr. Dorina Kallogjeri, will use a randomized block design for study drug assignment.
Intervention
The study intervention will be budesonide powder (0.5 mg/capsule) or an identical-appearing placebo product containing lactose. All subjects will be provided with the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle Kit and a one-month supply of USP Grade Sodium Chloride & Sodium Bicarbonate Mixture (pH balanced, Isotonic & Preservative & Iodine Free) commercially prepared packettes. Subjects may substitute the NeilMed Sinus Rinse Regular Bottle Kit for a nasal irrigation system, which in the opinion of the Principal Investigator, is similar to the NeilMed system and embodies the low-pressure, high-volume concept of nasal irrigation. Examples of such systems include, but are not limited to, ceramic or plastic neti pot or nasal douch (Nasendusche). Subjects will need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily. The subjects will receive written instructions and a video prior to initiation of the intervention to ensure proper delivery.
Each study bottle will contain 60 capsules of Budesonide or placebo and will be assigned with a number from 1-80. Only Dr. Kallogjeri (biostatistician) will have a list that links the treatment type (Budesonide or placebo) with the bottle number. The bottle number will correspond to the randomization schedule provided from Dr. Kallogjeri. The subject and the rest of the study team will remain blinded to the randomization assignment. The subject and the rest of the study team will only know what bottle number is being assigned, not which treatment is contained in each bottle. Dr. Kallogjeri is the biostatistician of the study and otherwise is not involved with the participants.
In the event of a Serious Adverse Event determined by the PI to necessitate the breaking of the blind, the intervention assignment will be revealed by Dr. Kallogjeri to the medical staff doctor caring for the Neti-Cort v3.0
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The active drug and placebo will be prepared by Genesis Pharmacy, St. Louis Missouri and delivered to the Clinical Outcomes Office where the products will be stored in a locked cabinet. The cost of sufficient budesonide for the study duration (i.e., 60 budesonide capsules) will be $75 and the cost of sufficient quantity of lactose capsules will be $25.
Budesonide
Budesonide is an anti-inflammatory glucocorticoid steroid that is used for a variety of common ailments. Among conditions related to the respiratory tract, budesonide is used as an inhalational drug for the treatment of asthma, COPD, allergic rhinitis, and nasal polyps. The mechanism of action of budesonide is similar to other corticosteroids and includes a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic-and non-allergic-mediated inflammation.(AstraZeneca 2000 2000)
Subjects randomized to the budesonide intervention arm will be required to mix 1.0 mg (provided as two capsules containing 0.5 mg budesonide each) budesonide into the sinus rinse bottle and rinse each nasal cavity with one half of the bottle (~ 4 ounces or ~120 ml) daily. The inert ingredients are: loxasperse powder, which increases solubility and dispersibility of budesonide and is microbiologically safe; mannitol, which is widely used in pharmaceutical products as a capsule diluent; and Xylifos powder, which is a proprietary powder excipient used safely in pharmaceutical compounding for nasal nebulization or nasal irrigation.
Placebo
The placebo product will contain lactose monohydrate and will be supplied in clear plastic capsules, which are identical to the budesonide capsules. The lactose capsule will only contain lactose as there are no other ingredients.
Concomitant Medications
At the time of enrollment, most subjects will be expected to already be using topical nasal steroid medication (ie., fluticasone or Flonase®). Subjects currently using a topical nasal steroid spray will be asked to continue this medication. Subjects not currently using a topical steroid spray will be asked to initiate therapy, unless there is a contraindication or personal reason for not wishing to use. Topical nasal steroid sprays are indicated therapy for CRS and not considered experimental.
Patient-reported Outcome Measure
The SNOT-22 (©2006, Washington University, St. Louis, MO) will be used to capture the physical, functional, and emotional consequences of rhinosinusitis. The SNOT-22 is a validated, patient-reported outcome measure applicable to chronic sinonasal conditions. 36 The 
Primary Outcome Measure
Study participants will be asked to complete the SNOT-22 at baseline, two weeks, and four weeks. The change in SNOT-22 scores between baseline and four weeks will serve as the primary outcome measure in this study and will be calculated as:
Primary Outcome Measure, ∆SNOT-22 = SNOT-22 baseline SNOT-22 4-week follow-up .
To assess the trajectory of change within subjects randomized to the two treatment arms the baseline, two-week, and four-week SNOT-22 assessment will be compared.
Secondary Outcome Measure.
The overall response to treatment will be measured with a modification of the Clinical Global Impression (CGI) scale. 39 Upon completion of the study, subjects will be asked to answer the following question: CT evidence of inflammation of the sinuses will be defined as mucosal thickening of at least one have a Lund and MacKay score of 1 or greater.
Data Collection
Sources of Research Material All research-related information, including responses to the selected patient-reported outcome measures, will be captured electronically via the use of dedicated iPADs. Week 2 patient-reported outcome measures will be captured via email link sent to subjects with RedCAP capture. All data will be stored in a specially designed database created by staff in the Clinical Outcomes Research Office using REDCap (Research Electronic Data Capture) software. Patient confidentiality will be maintained through the use of unique patient ID.
Assessment of Treatment Efficacy
The change in the average SNOT-22 scores between baseline and four weeks will serve as the primary outcome measure in this study and will be calculated as:
Assessment of Treatment Safety -Treatment safety will be assessed by patient interview and will include collection of adverse events experienced by the patient during the four week participation.
Risk Assessment
Budesonide has a potent glucocorticoid activity and weak mineralocorticoid activity. As an inhaled product, budesonide has an onset of action in 24 hours and peak effect in 1-2 weeks. The drug is welltolerated and the more frequent side effects include: nose irritation, epistaxis, lightheadedness, and upset stomach. 
Data and Safety Monitoring
The Clinical Outcomes Research Office (CORO) created a set of Standard Operating Procedures (SOPs) for the conduct of clinical research. These SOPS are developed, in part, from and are compliant with Institutional guidelines for the conduct of human research.
The specific monitoring plan for this study is based on the potential risk of participation and size and complexity of the planned investigation. Based on these considerations this study will have a monitoring board comprised of Drs. Piccirillo, Schneider, and Ms. Kukuljan knowledgeable about the risks of topically applied glucocorticosteroid, nasal anatomy, and Dr. Kallogjeri, the study biostatistician.
All three individuals will not be part of the core study team. All reports of a Serious Adverse Event (SAE) or an Unexpected Adverse Event will be investigated by the monitoring team. All SAEs will be reported to Washington University HRPO.
Statistical Analysis
Comparison of within subject difference in SNOT22 scores between baseline and four-week follow-up between the 2 treatment groups will be the primary outcome measure. A clinically meaningful change is defined as a change of 9 or more on the SNOT22. Independent samples t-test will be used to test for statistically significan "NOT-22
between 2 treatment groups.
The statistical significance of the observed difference in the percentage of subjects who achieve a clinically meaningful difference will be assessed with the chi-square statistic. The 95% confidence interval around the observed difference in the percentage of subjects who achieve a clinically meaningful difference will be calculated.
To assess the time trajectory of change within subjects randomized to the two treatment arms, the baseline, two-week, and four-week SNOT-22 assessments will be computed and compared. Within group differences will be compared using a repeated measure ANOVA. A general linear model (GLM) approach will be used to explore through the testing of an interaction effect (treatment group x time) whether the magnitude and pattern of change in SNOT-22 scores at baseline, 2 weeks, and 4 weeks is different between the 2 treatment groups. In addition to allowing for exploration of the interaction effect, the GLM model allows for evaluation of estimated means after controlling for potential confounders. A robust regression model will be used if the assumption of the GLM model will not be met.
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The distribution of responses on the Clinical Global Impression (CGI) scale will be calculated within each intervention arm and the difference in responses between the two intervention arms will be compared for statistical significance with the chi-square statistic. All of the above analyses will be repeated within subgroups of nasal polyp and previous surgery subjects.
All statistical analyses will be performed with SAS software. Statistical significance will be defined as a two-tailed test of significance p value of 0.05 or less.
An interim analysis will be performed after Subject 32 has completed 4-week treatment. Stopping rules based on the work of O'Brien and Fleming 41 for the conduct of clinical trials will be followed.
An Intention-to-Treat analysis will be used for the final data analyses.
Sample Size Calculations
The sample size for this study was estimated using preliminary data from CRS patients undergoing steroid irrigations after sinus surgery. In addition our goal is to be able to detect a clinically meaningful difference of 0.8 points or greater in the change in SNOT-22 scores (pre-post) (equivalent to change of 9 or more points in the overall SNOT22 score) between the 2 treatment groups. Assuming that the variability (SD=1.1) in pre-post changes in SNOT-22 scores reported from Snidvong et al. will remain true in our data we estimated that we will need 32 subjects per group (total n=64) to be able to detect with 80% power at the 2 sided alpha level of 0.05 a difference of 0.8 points or greater in the in SNOT-22 score changes between the 2 treatment groups. We plan to enroll 80 subjects in total as we assume a 20% drop out/non-compliance rate.
Remuneration
Subjects will receive $45 after baseline and $45 at final visit and upon successful completion of trial.
Timeline of the Study
Subjects will be enrolled in the study for a total of four weeks. Given the volume of patients seen at the Adult Otolaryngology service with diagnosis of CRS, we anticipate it will take one year to complete enrollment.
